-

Bayer Completes Sale of Its Environmental Science Professional Business to Cinven

Business to continue operations as an independent company called Envu

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer has completed the sale of its Environmental Science Professional business to the international private equity firm Cinven, after the two companies had entered into a corresponding agreement in March. The conditions for closing the transaction – including the receipt of regulatory approval – have now been met. The purchase price for the business, which generated sales of approximately 600 million euros in 2021, amounts to 2.6 billion U.S. dollars.

“We thank the employees of Environmental Science Professional for their many years of commitment and the associated success of Bayer. In Cinven, we have found a strong new owner with a firm commitment to the long-term growth potential of the business and to its people,” said Rodrigo Santos, member of the Board of Management of Bayer AG and head of the Crop Science Division. “At the same time, we can concentrate on our core agricultural business and the successful implementation of our growth strategy in the Crop Science Division.” Bayer will use the net proceeds from the transaction to reduce its net financial debt.

The divested business is set to operate as an independent company called Envu. The business is a global leader offering solutions to control pests, disease and weeds in non-agricultural areas such as vector control, professional pest management, vegetation management, forestry, and turf and ornamentals. It is headquartered in Cary, North Carolina, United States, and is active in over 100 countries. Nearly 900 employees in total will transfer from Bayer to Envu.

“Envu is a global leader in a highly attractive and critical industry. We thank Bayer for the trust they have placed in Cinven and plan to build on the strong foundations established by Bayer by significantly investing in it,” said Pontus Pettersson, Partner at Cinven. “Cinven is excited to build an independent, focused company and is well positioned to continue to drive innovation and accelerate growth, including the delivery of digital and data-enabled solutions, and to extend the product portfolio further by creating innovative and sustainable solutions for its customers.”

About Envu

Envu was founded in 2022, a new company built on years of Bayer experience, for the sole purpose of advancing healthy environments for everyone, everywhere. Envu offers dedicated services in: Professional Pest Management, Forestry, Ornamentals, Golf, Industrial Vegetation Management, Lawn & Landscape, Mosquito Management, and Range & Pasture. Across each of its lines of business, Envu focuses its work in chemistry and beyond, collaborating with customers to come up with innovative solutions that will work today and well into the future. Envu’s portfolio consists of over 180 trusted and well-known brands. The company employs nearly 900 people and operates in more than 100 countries with four global innovation hubs. For additional information, visit the Envu website.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com.

About Cinven

Cinven is a leading international private equity firm focused on building world-class global companies. Its funds invest in six key sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials and TMT (Technology, Media and Telecommunications). Cinven has offices in London, New York, Frankfurt, Paris, Milan, Madrid, Guernsey and Luxembourg. Cinven takes a responsible approach towards its portfolio companies, their employees, suppliers, local communities, the environment and society. www.cinven.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Contact for media inquiries:
Bayer AG
Dr. Rolf Ackermann, phone +49 214 30-41782
Email: rolf.ackermann@bayer.com

Envu
Jennifer Poore, Tel. +1 919 475-5814
E-Mail: jennifer.poore@envu.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com
www.bayer.com/en/investors/ir-team

Find more information at www.bayer.com.
Follow us on Twitter https://twitter.com/bayer

Bayer


Release Versions

Contacts

Contact for media inquiries:
Bayer AG
Dr. Rolf Ackermann, phone +49 214 30-41782
Email: rolf.ackermann@bayer.com

Envu
Jennifer Poore, Tel. +1 919 475-5814
E-Mail: jennifer.poore@envu.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com
www.bayer.com/en/investors/ir-team

Find more information at www.bayer.com.
Follow us on Twitter https://twitter.com/bayer

More News From Bayer

Bayer Highlights New Data from Oncology and Women’s Health Portfolios at 2025 ASCO Annual Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer’s oncology and women’s health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 30–June 3. These data underscore Bayer’s commitment to advancing treatments across different stages of cancer and driving the development of healthcare treatments, including for prostate and lung cancer. This year’s ASCO presence also underscores Bay...

U.S. FDA Grants Approval for Jivi® Antihemophilic Factor (Recombinant), PEGylated-aucl in Pediatric Patients 7 to Under 12 Years of Age With Hemophilia A (Congenital Factor VIII Deficiency)

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi®, a recombinant DNA-derived, extended half-life factor VIII concentrate, for use in pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency). The approval is based on data from the Alfa-PROTECT and PROTECT Kids studies, demonstrating Jivi’s safety and efficacy in children aged 7 to under 12 years with severe hemophilia A. This significant m...

Passage of New Georgia Bill a Win for Farmers

ST. LOUIS--(BUSINESS WIRE)--Farmers and others in agriculture applaud Governor Brian Kemp and the Georgia General Assembly for supporting the crop protection tools so important to Georgia’s farmers’ ability to produce affordable, safe, abundant food. With Governor Kemp signing SB 144, Georgia has taken the step to re-affirm the authority of the U.S. Environmental Protection Agency’s (EPA) scientific rulings on the safety of crop protection products. “The signing of SB 144 by Governor Kemp demon...
Back to Newsroom